Application of a novel liquid biopsy in patients with hepatocellular carcinoma undergoing liver transplantation

Xue, Feng; Shi, Shaojun; Zhang, Zhenzhen; Xu, Chen; Zheng, Jian Xin; Qin, Tian; Qian, Zhiyu; Zhao, Xiaoyu; Tong, Ying; Xia, Lei; Xia, Qiang

doi:10.3892/ol.2018.8019

Cited by 23 publications

(34 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another study using this platform also failed to uncover significant associations between change in total CTCs or CTC subtypes and HCC recurrence in a cohort consisting of 47 patients who underwent liver transplantation [96] . Nevertheless, Xue et al [97] utilized an iFISH® platform to detect CTCs in patients undergoing liver transplantation and found that patients with preoperative iFISH-CTCs ≥ 5 in 7.5 mL of blood had significantly shorter recurrence-free survival than those with lower CTCs. Further large, multicenter studies are still needed to confirm the association between different molecular phenotypes of CTCs and HCC prognosis.…”

Section: Early Detection and Prediction Of Tumor Progression In Hccmentioning

confidence: 99%

Detection of circulating tumor cells in hepatocellular carcinoma: applications in diagnosis, prognosis prediction and personalized treatment

Wang¹,

Yang²

2020

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is one of the most common malignant tumors worldwide and is associated with poor clinical prognosis, which is mainly caused by tumor recurrence and metastasis. Circulating tumor cells (CTCs) are tumor cells shed into the bloodstream and regarded as the "seeds" of tumor recurrent or metastatic lesions. Over the past decade, the clinical value of CTC analysis has been extensively explored. CTC analysis is a representative form of liquid biopsy, offering a novel solution that can bypass the problems of invasive biopsy procedures, enabling comprehensive, non-invasive, and real-time disease monitoring. In HCC, CTC analysis has facilitated early detection and prognosis prediction, as well as treatment monitoring and therapeutic intervention guiding. In this review, we summarize available literature and provide an overview of CTC biology, detection technologies, and clinical applications in the diagnosis, prognosis prediction, and personalized treatment of HCC.

show abstract

Section: Early Detection and Prediction Of Tumor Progression In Hccmentioning

confidence: 99%

Detection of circulating tumor cells in hepatocellular carcinoma: applications in diagnosis, prognosis prediction and personalized treatment

Wang¹,

Yang²

2020

View full text Add to dashboard Cite

show abstract

“…In patients undergoing LT, an independent association between recurrence-free survival after LT and preoperative CTCs count was demonstrated 136. Even in patients with low AFP levels, CTCs count still predicted outstanding recurrence rates 136. Nevertheless, no significant association was observed between HCC recurrence after LT and total CTCs change or CTCs subtype in another study,137 probably related to its insufficient statistical power due to the small sample size.…”

Section: Liquid Biopsymentioning

confidence: 93%

“…A CTCs count slope is also associated with disease progression,133 and the persistence of CTCs after a potentially curative therapy may be an independent prognostic factor 134,135. In patients undergoing LT, an independent association between recurrence-free survival after LT and preoperative CTCs count was demonstrated 136. Even in patients with low AFP levels, CTCs count still predicted outstanding recurrence rates 136.…”

Section: Liquid Biopsymentioning

confidence: 99%

Selecting patients with hepatocellular carcinoma for liver transplantation: incorporating tumor biology criteria

Amado¹,

Rodríguez‐Perálvarez²,

Ferrín³

et al. 2018

JHC

View full text Add to dashboard Cite

Liver transplantation (LT) is the optimal therapeutic option for patients with liver cirrhosis and hepatocellular carcinoma (HCC). Due to universal donor shortage, only the patients with limited tumor burden (under the so-called Milan criteria) are considered as potential candidates for LT in most institutions. It is expected that in the near future, more liver grafts will be available for patients with HCC due to the implementation of new direct antivirals against hepatitis C, leaving a prone scenario to consider expanding Milan criteria. A moderate expansion of Milan criteria could be implemented without increasing the risk of tumor recurrence if patients with favorable biological behavior are carefully selected. Incorporating information regarding tumor biology in the decision-making algorithm would result in a more rational use of LT in patients with HCC. In the present review, surrogate markers of tumor biology are critically evaluated as potential tools to be combined with existing radiological criteria. In addition, the current state of liquid biopsy is discussed, as this cutting-edge technology may reshape the management of HCC in the upcoming years.

show abstract

“…( 58,59 ) However, data in the transplant setting remain controversial with 1 study showing shorter recurrence‐free survival after LT in patients with detectable CTCs compared with those without CTCs (6 versus 15 months). ( 60 ) Another study showed no definitive predictive capacity from CTC enumeration. ( 61 ) The main limitation of these technologies is the relatively low sensitivity and lack of reproducibility across different technologies.…”

Section: Molecular Biomarkers For Hcc Risk Stratification In Ltmentioning

confidence: 99%

Role of Molecular Biomarkers in Liver Transplantation for Hepatocellular Carcinoma

Felden¹,

Villanueva

2020

Liver Transpl

View full text Add to dashboard Cite

Patient selection and organ allocation for liver transplantation (LT) in patients with hepatocellular carcinoma (HCC) relies predominantly on clinical parameters, such as tumor burden (ie, radiological imaging). Patients transplanted withinMilan criteria have outstanding outcomes with a 5-and 10-year survival of 70% and 55%, respectively. Tumor recurrence after transplantion is rare in these patients (10%); however, treatment options upon recurrence are generally limited, and outcomes are poor. There are also several studies showing how a subgroup of patients with tumors outside the Milan criteria might achieve comparable outcomes to patients within Milan criteria. In other words, the size and number of tumor nodules does not always reflect tumor biology, which could be better captured using molecular proxies for cancer aggressiveness. Over the last decade, we have significantly improved our understanding of the molecular landscape of early stage HCC. This includes the development of molecular classification, identification of prognostic and mutational signatures, and potential mechanisms of hepatocarcinogenesis. Some molecular markers have already proven useful to predict tumor-related outcomes in HCC patients after LT. Most of these analyses are limited to tissue-derived biomarkers, which limits their implementation in clinical practice because tissue biopsy is not required for HCC diagnosis. Minimally invasive alternative tools, such as liquid biopsy, are being increasingly explored and could help to individualize risk stratification for patients with HCC who will benefit from LT despite being outside the accepted clinical criteria.Liver Transplantation 26 823-831 2020 AASLD.

show abstract

Application of a novel liquid biopsy in patients with hepatocellular carcinoma undergoing liver transplantation

Cited by 23 publications

References 25 publications

Detection of circulating tumor cells in hepatocellular carcinoma: applications in diagnosis, prognosis prediction and personalized treatment

Detection of circulating tumor cells in hepatocellular carcinoma: applications in diagnosis, prognosis prediction and personalized treatment

Selecting patients with hepatocellular carcinoma for liver transplantation: incorporating tumor biology criteria

Role of Molecular Biomarkers in Liver Transplantation for Hepatocellular Carcinoma

Contact Info

Product

Resources

About